{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(1)"],"submitter":["Chebbi P"],"pubmed_abstract":["<h4>Introduction</h4>We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib.<h4>Methods</h4>This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded.<h4>Results</h4>During the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib we"],"journal":["BMC rheumatology"],"pagination":["22"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10369741"],"repository":["biostudies-literature"],"pubmed_title":["Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset."],"pmcid":["PMC10369741"],"pubmed_authors":["Pinto B","Rao VK","Janardana R","Tekkatte R","Chebbi P","Mahendranath KM","Patil A","Salanke M","Shobha V","Haridas V","Kumar S"],"additional_accession":[]},"is_claimable":false,"name":"Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.","description":"<h4>Introduction</h4>We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib.<h4>Methods</h4>This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded.<h4>Results</h4>During the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib we","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2025-04-22T00:59:50.655Z","creation":"2024-11-20T11:52:30.037Z"},"accession":"S-EPMC10369741","cross_references":{"pubmed":["37496101"],"doi":["10.1186/s41927-023-00345-8"]}}